JACOB RIDDER: Open Payments
NPI 1508291717 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,369 in 90 payments from 18 companies in 2025. Trend: 2023 $1,958 · 2024 $2,277 · 2025 $4,369
Consulting: $2,370Food & beverage: $1,824Education: $175
| Company | Payments | Amount |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4 | $1,449 |
| Arcutis Biotherapeutics, Inc. | 6 | $1,240 |
| GENZYME CORPORATION | 4 | $263 |
| Regeneron Healthcare Solutions, Inc. | 5 | $178 |
| ABBVIE INC. | 9 | $164 |
| PFIZER INC. | 18 | $148 |
| Lilly USA, LLC | 9 | $142 |
| E.R. Squibb & Sons, L.L.C. | 11 | $140 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $104 |
| Incyte Corporation | 4 | $103 |
Products named: DUPIXENT, Zoryve, SKYRIZI, CIBINQO, Sotyktu, TALTZ, OPZELURA, TREMFYA.
Industry payments across NE — which companies pay providers there.
